ANGO ANGIODYNAMICS INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1275187 · Fiscal year ends 05/31
Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.2%
TTM net income YoY-2.6%
TTM EPS YoY-1.3%
Revenue 3-yr CAGR-1.1%
Net income 3-yr CAGR—
Margins
Gross margin55.7%
Operating margin-11.2%
Net margin-10.1%
FCF margin0.4%
EBITDA margin-4.3%
Returns
ROE-19.2%
ROA-13.0%
ROIC (approx.)-21.4%
Asset turnover1.28x
Leverage & solvency
Liabilities / assets32.2%
Debt / equity0.00x
Current ratio2.40x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.11x
Accruals ratio-14.4%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-08-31 | 2026Q4*2026-05-31 | 2026Q32026-02-28 | 2026Q22025-11-30 | 2026Q12025-08-31 | 2025Q4*2025-05-31 | 2025Q32025-02-28 | 2025Q22024-11-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $80.92M | $86.61M | $78.42M | $79.43M | $75.71M | $80.16M | $72.00M | $72.84M |
| Cost of revenue | $32.88M | $39.83M | $36.94M | $34.65M | $33.85M | $37.94M | $33.15M | $32.94M |
| Gross profit | $48.04M | $46.77M | $41.48M | $44.78M | $41.86M | $42.22M | $38.86M | $39.91M |
| R&D expense | $7.98M | $8.18M | $7.08M | $7.77M | $6.42M | $6.59M | $6.91M | $6.43M |
| SG&A expense | $12.47M | $10.27M | $10.72M | $10.15M | $12.55M | $10.24M | $10.49M | $10.39M |
| Operating income | -$7.30M | -$10.20M | -$12.95M | -$6.12M | -$10.66M | -$5.79M | -$9.97M | -$11.09M |
| Pretax income | -$7.30M | -$11.04M | -$8.07M | -$6.36M | -$10.84M | -$6.11M | -$4.41M | -$10.85M |
| Income tax | -$199,000 | $370,000 | $12,000 | -$5,000 | $65,000 | -$60,000 | -$2,000 | -$110,000 |
| Net income | -$7.10M | -$11.40M | -$8.08M | -$6.35M | -$10.90M | -$6.05M | -$4.41M | -$10.74M |
| EBITDA | -$1.80M | -$4.60M | -$7.36M | -$378,000 | -$4.71M | $45,000 | -$3.65M | -$4.23M |
| EPS (basic) | -0.17 | — | -0.19 | -0.15 | -0.26 | — | -0.11 | -0.26 |
| EPS (diluted) | -0.17 | — | -0.19 | -0.15 | -0.26 | — | -0.11 | -0.26 |
| Weighted avg. shares (diluted) | 42.02M | — | 41.60M | 41.54M | 41.17M | — | 40.85M | 40.92M |
| Balance sheet | ||||||||
| Cash & equivalents | $33.97M | $53.86M | $37.81M | $41.64M | $38.76M | $55.89M | $44.76M | $54.09M |
| Receivables | $44.91M | $48.33M | $45.55M | $44.43M | $42.64M | $42.89M | $43.47M | $43.16M |
| Inventory | $54.95M | $52.44M | $58.58M | $65.57M | $62.26M | $62.01M | $63.10M | $65.92M |
| Current assets | $143.00M | $163.39M | $155.55M | $161.35M | $156.66M | $168.32M | $172.27M | $175.36M |
| PP&E, net | $27.73M | $27.10M | $29.14M | $30.53M | $31.07M | $32.30M | $32.53M | $32.98M |
| Intangibles | $61.89M | $67.21M | $65.49M | $66.73M | $68.38M | $69.12M | $70.93M | $73.11M |
| Total assets | $241.93M | $267.16M | $260.68M | $269.68M | $265.64M | $280.14M | $285.42M | $291.55M |
| Current liabilities | $59.69M | $74.72M | $66.07M | $71.96M | $68.28M | $76.20M | $77.97M | $88.59M |
| Total liabilities | $77.97M | $96.34M | $87.32M | $93.35M | $86.79M | $97.17M | $99.55M | $104.78M |
| Shareholders' equity | $163.96M | $170.82M | $173.36M | $176.33M | $178.85M | $182.97M | $185.87M | $186.77M |
| Shares outstanding | 42.42M | 41.70M | 41.68M | 41.57M | 41.45M | 40.99M | 40.97M | 40.84M |
| Cash flow statement | ||||||||
| Operating cash flow | -$15.33M | $17.45M | -$3.11M | $4.66M | -$15.91M | $18.81M | -$13.16M | $2.47M |
| Capital expenditure | $379,000 | $413,000 | $1.01M | $422,000 | $731,000 | $777,000 | $1.80M | $797,000 |
| Free cash flow | -$15.71M | $17.04M | -$4.12M | $4.24M | -$16.64M | $18.03M | -$14.96M | $1.68M |
| Investing cash flow | -$3.15M | -$1.27M | -$1.51M | -$1.62M | -$1.55M | -$2.62M | -$3.19M | -$1.96M |
| Financing cash flow | -$1.38M | -$108,000 | $621,000 | -$92,000 | $143,000 | -$5.77M | $7.15M | -$1.12M |
| Depreciation & amortization | $5.50M | $5.60M | $5.59M | $5.75M | $5.95M | $5.83M | $6.32M | $6.86M |
| Stock-based compensation | $4.50M | $3.92M | $2.70M | $2.90M | $4.47M | $1.64M | $2.40M | $2.50M |
| Share buybacks | — | $0 | $0 | $0 | $0 | $0 | $0 | $1.12M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.